Chief of Myeloma Division, Director of Myeloma Research Institute University of Miami, Sylvester Comprehensive Cancer Center Pinecrest, Florida, United States
Description: The advent of large-scale genomic studies has transformed our understanding of multiple myeloma (MM), revealing a complex landscape of molecular subtypes that transcend traditional classifications. This presentation will explore the emerging genomic taxonomy of MM, with a focus on the integrative models that combine DNA- and RNA-based features to define biologically and clinically distinct subgroups. We will review how these findings inform prognosis, therapeutic response, and risk stratification—laying the groundwork for future precision medicine approaches.
Learning Objectives: - Describe the key genomic alterations that define molecular subtypes of multiple myeloma. - Explain how integrative genomic classification refines risk stratification beyond conventional staging systems. - Evaluate the role of genomic profiling in the evolving landscape of precision medicine for multiple myeloma.
